HNWAG
HOWL icon

High Net Worth Advisory Group’s Werewolf Therapeutics HOWL Stock Holding History

High Net Worth Advisory Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$6K – 698
2021
Q4 		$6K Buy
+500
New +$7.54K ﹤0.01% 581

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

High Net Worth Advisory Group's HOWL Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Werewolf Therapeutics (HOWL) in Q1 2022, closing a stake of 500 shares — an estimated $6K sold.

High Net Worth Advisory Group first reported a position in HOWL in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 49 funds tracked by Wall St. Rank hold HOWL as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Werewolf Therapeutics position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Werewolf Therapeutics shares in Q1 2022, an estimated $6K.
  • High Net Worth Advisory Group first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Werewolf Therapeutics position peaked at $6K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.